Mutant KRAS-Driven Selective mRNA Translation Reveals Mechanisms and Therapeutic Vulnerabilities in Cancer
RNA-seq (gene expression) · human · 48 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 48 samples: 48 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE285857_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1206226 and SRA study SRP555235. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 48 sample titles: 48 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8711411 MiaPaca2 DMSO-1 RF
- GSM8711412 MiaPaca2 DMSO-2 RF
- GSM8711413 MiaPaca2 DMSO-3 RF
- GSM8711414 MiaPaca2 Soto-1 RF
- GSM8711415 MiaPaca2 Soto-2 RF
- GSM8711416 MiaPaca2 Soto-3 RF
- GSM8711417 MiaPaca2 Harr-1 RF
- GSM8711418 MiaPaca2 Harr-2 RF
- GSM8711419 MiaPaca2 Harr-3 RF
- GSM8711420 MiaPaca2 Soto-Harr-1 RF
- GSM8711421 MiaPaca2 Soto-Harr-2 RF
- GSM8711422 MiaPaca2 Soto-Harr-3 RF
- GSM8711423 Panc10.05 DMSO-1-1 RF
- GSM8711424 Panc10.05 DMSO-1-2 RF
- GSM8711425 Panc10.05 DMSO-1-3 RF
- GSM8711426 Panc10.05 MRTX1133-1-1 RF
- GSM8711427 Panc10.05 MRTX1133-1-2 RF
- GSM8711428 Panc10.05 MRTX1133-1-3 RF
- GSM8711429 Panc10.05 DMSO-2-1 RF
- GSM8711430 Panc10.05 DMSO-2-2 RF
- GSM8711431 Panc10.05 DMSO-2-3 RF
- GSM8711432 Panc10.05 Harr-2-1 RF
- GSM8711433 Panc10.05 Harr-2-2 RF
- GSM8711434 Panc10.05 Harr-2-3 RF
- GSM8711435 MiaPaca2 DMSO-1 RNA
- GSM8711436 MiaPaca2 DMSO-2 RNA
- GSM8711437 MiaPaca2 DMSO-3 RNA
- GSM8711438 MiaPaca2 Soto-1 RNA
- GSM8711439 MiaPaca2 Soto-2 RNA
- GSM8711440 MiaPaca2 Soto-3 RNA
- GSM8711441 MiaPaca2 Harr-1 RNA
- GSM8711442 MiaPaca2 Harr-2 RNA
- GSM8711443 MiaPaca2 Harr-3 RNA
- GSM8711444 MiaPaca2 Soto-Harr-1 RNA
- GSM8711445 MiaPaca2 Soto-Harr-2 RNA
- GSM8711446 MiaPaca2 Soto-Harr-3 RNA
- GSM8711447 Panc10.05 DMSO-1-1 RNA
- GSM8711448 Panc10.05 DMSO-1-2 RNA
- GSM8711449 Panc10.05 DMSO-1-3 RNA
- GSM8711450 Panc10.05 MRTX-1-1 RNA
+ 8 more — browse all 48 samples with per-sample file links →
- GSE294016 A macrophage-predominant, immunosuppressive immune microenvironment and subtype-specific therapeutic vulnerabilities in advanced salivary gland cancer [bulk RNA-seq] 95 samples shares vulnerabilities, therapeutic
- GSE319124 Next-GenerationPediatric Cancer Models: Patient-Matched Orthotopic Xenografts, 3D Organoids, 2D Cultures, and Cell Lines for Identification of Therapeutic Vulnerabilities in Pediatric Solid Tumors [scRNAseq] 59 samples shares vulnerabilities, therapeutic
- GSE294017 A macrophage-predominant, immunosuppressive immune microenvironment and subtype-specific therapeutic vulnerabilities in advanced salivary gland cancer [Single nuclei RNAseq] 16 samples shares vulnerabilities, therapeutic
- GSE236589 Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer [ChIP-Seq] 12 samples shares therapeutic, mutant
- GSE248572 m6A sites in the coding region trigger translation-dependent mRNA decay (ribosome profiling) 12 samples shares translation, mrna
- GSE275870 Expression profiling of primary and metastatic oral squamous cell carcinoma identifies progression-associated transcriptome changes and therapeutic vulnerabilities 108 samples shares vulnerabilities, therapeutic
- GSE305263 Integrated RNA, translation, and proteome profiling reveals midbody remnants as selectively organized signaling vesicles 42 samples shares translation, selective
- GSE290866 Programmable mRNA Therapeutics for Controlled Epigenomic Modulation of Single and Multiplexed Gene Expression in Diverse Diseases (human data) 20 samples shares therapeutic, mrna
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.